A combination of Apigenin and Cetuximab (a well-known epidermal growth factor receptor inhibitor) could effectively suppress the viability of NPC cells by increasing G2/M phase arrest (Hu et al., 2018). This evidence concerns the gene EGFR and nasopharyngeal carcinoma.